U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07338370) titled 'Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates' on Jan. 03.
Brief Summary: prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.
Study Start Date: Jan., 2026
Study Type: OBSERVATIONAL
Condition:
Neonatal Prematurity
Patent Ductus Arteriosus in Preterm Infants
Prostaglandins
Intervention:
DRUG: Ibuprofen (Brufen(R))
Group1will receive anti-PGE; Ibuprofen (IBU) (brufen)(R) syrup will be given for 3 days enteral...